View Alert


Originator: CMO Messaging

From: CMO Messaging

Issue date: 25-Nov-2020 10:58:53

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health

Action category: Action

Title: Publication of an interim position statement: Tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults)

Broadcast content:
Following early positive signals of benefit from the immune modulation therapy domain of the REMAP-CAP platform trial, a UK wide position statement has been agreed to support off-label prescribing and access to tocilizumab, administered intravenously, for eligible COVID positive patients in the intensive care setting.

The interim position statement will be reviewed as further evidence becomes available, including from the REMAP-CAP trial.

Further information can be found in the attached alert.
The position statement is also attached.


Additional information: This alert does not need to be cascaded to primary care.

Alert reference: CEM/CMO/2020/038

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency